Shadow of diabetes over cardiovascular disease: comparative quantification of population-attributable all-cause and cardiovascular mortality

Cardiovascular Diabetology

Volumn 11, Issue , 2012, Pages

  Bozorgmanesh, Mohammadreza ^a   Hadaegh, Farzad ^a   Sheikholeslami, Farhad ^a   Ghanbarian, Arash ^a   Azizi, Fereidoun ^b  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cardiovascular disease; Diabetes; Mortality; Population attributable mortality

Indexed keywords

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; DIABETES MELLITUS; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; IRAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREVALENCE; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; RISK FACTOR;

ADOLESCENT; ADULT; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; IRAN; LINEAR MODELS; MALE; MIDDLE AGED; PREVALENCE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; YOUNG ADULT;

EID: 84862188324     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-11-69     Document Type: Article

References (56)

1. Tuomilehto J, Rastenyte D, Birkenhäger WH, Thijs L, Antikainen R, Bulpitt CJ, Fletcher AE, Forette F, Goldhaber A, Palatini P, et al. Effects of Calcium-Channel Blockade in Older Patients with Diabetes and Systolic Hypertension. New England Journal of Medicine 1999, 340:677-684. 10.1056/NEJM199903043400902, 10053176.
2. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572.
3. Edejer TT-T. Disseminating health information in developing countries: the role of the internet. BMJ 2000, 321:797-800. 10.1136/bmj.321.7264.797, 1118616, 11009519.
4. Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal T, Hemmingsen C, Wetterslev J. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ 2011, 343:d6898. 10.1136/bmj.d6898, 3223424, 22115901.
5. Chen G, McAlister FA, Walker RL, Hemmelgarn BR, Campbell NRC. Cardiovascular Outcomes in Framingham Participants With Diabetes. Hypertension 2011, 57:891-897. 10.1161/HYPERTENSIONAHA.110.162446, 21403089.
6. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial Infarction. New England Journal of Medicine 1998, 339:229-234. 10.1056/NEJM199807233390404, 9673301.
7. Ghosh A, Castle PE. Invited commentary: the importance of prevalence in the effectiveness of a (bio)marker. Am J Epidemiol 2011, 173:1388-1390. discussion 1391, 10.1093/aje/kwr016, 3145395, 21571873.
8. Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Billot L, Woodward M, Ninomiya T, Neal B, MacMahon S, et al. Severe Hypoglycemia and Risks of Vascular Events and Death. New England Journal of Medicine 2010, 363:1410-1418. 10.1056/NEJMoa1003795, 20925543.
9. Wang WS, Wahlqvist ML, Hsu CC, Chang HY, Chang WC, Chen CC. Age-and gender-specific population attributable risks of metabolic disorders on all-cause and cardiovascular mortality in Taiwan. BMC Public Health 2012, 12:111. 10.1186/1471-2458-12-111, 3305485, 22321049.
10. Harati H, Hadaegh F, Saadat N, Azizi F. Population-based incidence of Type 2 diabetes and its associated risk factors: results from a six-year cohort study in Iran. BMC Public Health 2009, 9:186. 10.1186/1471-2458-9-186, 2708154, 19531260.
11. Hadaegh F, Bozorgmanesh MR, Ghasemi A, Harati H, Saadat N, Azizi F. High prevalence of undiagnosed diabetes and abnormal glucose tolerance in the Iranian urban population: Tehran Lipid and Glucose Study. BMC Public Health 2008, 8:176. 10.1186/1471-2458-8-176, 2413226, 18501007.
12. Gomez-Marcos MA, Recio-Rodríguez JI, Patino-Alonso MC, Agudo-Conde C, Gomez-Sanchez L, Rodriguez-Sanchez E, Gomez-Sanchez M, Garcia-Ortiz L. Yearly evolution of organ damage markers in diabetes or metabolic syndrome: data from the LOD-DIABETES study. Cardiovascular Diabetology 2011, 10:90. 10.1186/1475-2840-10-90, 3214163, 21999369.
13. Westman M, Etzion D, Danon E. Job insecurity and crossover of burnout in married couples. Journal of Organizational Behavior 2001, 22:467-481.
14. Nash ES. Teenage pregnancy-need a child bear a child. South African Medical Journal 1990, 77:147-151.
15. Trussell J. Teenage pregnancy in the United States. Family Planning Perspectives 1988, 20:262-272. 10.2307/2135482, 3229472.
16. Bozorgmanesh M, Hadaegh F, Sheikholeslami F, Azizi F. Cardiovascular risk and all cause mortality attributable to diabetes: Tehran Lipid and Glucose Study. J Endocrinol Invest 2011, 35:14-20.
17. Saito I, Kokubo Y, Yamagishi K, Iso H, Inoue M, Tsugane S. Diabetes and the risk of coronary heart disease in the general Japanese population: The Japan Public Health Center-based prospective (JPHC) study. Atherosclerosis 2011, 216:187-191. 10.1016/j.atherosclerosis.2011.01.021, 21300356.
18. Grau M, Subirana I, Elosua R, Fitó M, Covas MI, Sala J, Masiá R, Ramos R, Solanas P, Cordon F. Why should population attributable fractions be periodically recalculated?: An example from cardiovascular risk estimation in southern Europe. Preventive medicine 2010, 51:78-84. 10.1016/j.ypmed.2010.03.012, 20362610.
19. Kirby D. Emerging answers 2007: Research findings on programs to reduce teen pregnancy and sexually transmitted diseases. National Campaign to Prevent Teen and Unplanned Pregnancy. Retrieved February 2007, 23:2009.
20. Azizi F, Ghanbarian A, Momenan AA, Hadaegh F, Mirmiran P, Hedayati M, Mehrabi Y, Zahedi-Asl S. Prevention of non-communicable disease in a population in nutrition transition: Tehran Lipid and Glucose Study phase II. Trials 2009, 10:5. 10.1186/1745-6215-10-5, 2656492, 19166627.
21. Bozorgmanesh M, Hadaegh F, Khalili D, Azizi F. Prognostic significance of the Complex "Visceral Adiposity Index" vs. simple anthropometric measures: Tehran Lipid and Glucose Study. Cardiovascular Diabetology 2012, 11:20. 10.1186/1475-2840-11-20, 3376032, 22394430.
22. Freedman DS, Kahn HS, Mei Z, Grummer-Strawn LM, Dietz WH, Srinivasan SR, Berenson GS. Relation of body mass index and waist-to-height ratio to cardiovascular disease risk factors in children and adolescents: the Bogalusa Heart Study. Am J Clin Nutr 2007, 86:33-40.
23. Hadaegh F, Harati H, Ghanbarian A, Azizi F. Association of total cholesterol versus other serum lipid parameters with the short-term prediction of cardiovascular outcomes: Tehran Lipid and Glucose Study. Eur J Cardiovasc Prev Rehabil 2006, 13:571-577. 10.1097/01.hjr.0000216552.81882.ca, 16874147.
24. Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS, Ferguson TB, Fihn SD, Fraker TD, Gardin JM, et al. ACC/AHA 2002 Guideline Update for the Management of Patients With Chronic Stable Angina--Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation 2003, 107:149-158. 10.1161/01.CIR.0000047041.66447.29, 12515758.
25. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, Jones RH, Kereiakes D, Kupersmith J, Levin TN, et al. ACC/AHA Guideline Update for the Management of Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction--2002: Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation 2002, 106:1893-1900. 10.1161/01.CIR.0000037106.76139.53, 12356647.
26. Chen YQ, Hu C, Wang Y. Attributable risk function in the proportional hazards model for censored time-to-event. Biostatistics 2006, 7:515. 10.1093/biostatistics/kxj023, 16478758.
27. Samuelsen SO, Eide GE. Attributable fractions with survival data. Statistics in Medicine 2008, 27:1447-1467. 10.1002/sim.3022, 17694507.
28. Silverberg MJ, Smith MW, Chmiel JS, Detels R, Margolick JB, Rinaldo CR, O'Brien SJ, Muñoz A. Fraction of Cases of Acquired Immunodeficiency Syndrome Prevented by the Interactions of Identified Restriction Gene Variants. American journal of epidemiology 2004, 159:232-241. 10.1093/aje/kwh036, 14742283.
29. Laaksonen MA, Knekt P, Härkänen T, Virtala E, Oja H. Estimation of the Population Attributable Fraction for Mortality in a Cohort Study Using a Piecewise Constant Hazards Model. American journal of epidemiology 2010, 171:837-847. 10.1093/aje/kwp457, 20197386.
30. Siadat SH, Buyut VC, Selamat H. Measuring service quality in E-retailing using SERVQUAL model. IEEE 2008, 1-7.
31. Liese AD, Hense H-W, Brenner H, Löwel H, Keil U. Assessing the Impact of Classical Risk Factors on Myocardial Infarction by Rate Advancement Periods. American Journal of Epidemiology 2000, 152:884-888. 10.1093/aje/152.9.884, 11085401.
32. Abbate LM, Stevens J, Schwartz TA, Renner JB, Helmick CG, Jordan JM. Anthropometric measures, body composition, body fat distribution, and knee osteoarthritis in women. Obesity (Silver Spring) 2006, 14:1274-1281.
33. Levine B. Peer Reviewed: What Does the Population Attributable Fraction Mean?. Preventing chronic disease 2007, 4:A14. 1832135, 17173722.
34. Casiglia E, Zanette G, Mazza A, Donadon V, Donada C, Pizziol A, Tikhonoff V, Palatini P, Pessina AC. Cardiovascular mortality in non-insulin-dependent diabetes mellitus. A controlled study among 683 diabetics and 683 age- and sex-matched normal subjects. European Journal of Epidemiology 2000, 16:677-684. 10.1023/A:1007673123716, 11078126.
35. Smith NL, Barzilay JI, Kronmal R, Lumley T, Enquobahrie D, Psaty BM. New-Onset Diabetes and Risk of All-Cause and Cardiovascular Mortality. Diabetes Care 2006, 29:2012-2017. 10.2337/dc06-0574, 16936145.
36. Greenland P, Knoll MD, Stamler J, Neaton JD, Dyer AR, Garside DB, Wilson PW. Major Risk Factors as Antecedents of Fatal and Nonfatal Coronary Heart Disease Events. JAMA: The Journal of the American Medical Association 2003, 290:891-897.
37. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339:229-234. 10.1056/NEJM199807233390404, 9673301.
38. Folsom AR, Szklo M, Stevens J, Liao F, Smith R, Eckfeldt JH. A prospective study of coronary heart disease in relation to fasting insulin, glucose, and diabetes. The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care 1997, 20:935-942. 10.2337/diacare.20.6.935, 9167103.
39. Panzram G. Mortality and survival in Type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1987, 30:123-131. 10.1007/BF00274216, 3556287.
40. Stengård J, Tuomilehto J, Pekkanen J, Kivinen P, Kaarsalo E, Nissinen A, Karvonen M. Diabetes mellitus, impaired glucose tolerance and mortality among elderly men: The Finnish cohorts of the seven countries study. Diabetologia 1992, 35:760-765.
41. Buse JB. Should Postprandial Glucose Be Routinely Measured and Treated to a Particular Target?. No! Diabetes Care 2003, 26:1615-1618.
42. Leosdottir M, Willenheimer R, Persson M, Nilsson PM. The association between glucometabolic disturbances, traditional cardiovascular risk factors and self-rated health by age and gender: A cross-sectional analysis within the Malmö Preventive Project. Cardiovascular Diabetology 2011, 10:118. 10.1186/1475-2840-10-118, 3270001, 22204568.
43. Nishimura R, Nakagami T, Sone H, Ohashi Y, Tajima N. Relationship between hemoglobin A1c and cardiovascular disease in mild-to-moderate hypercholesterolemic Japanese individuals: subanalysis of a large-scale randomized controlled trial. Cardiovascular Diabetology 2011, 10:1-6. 10.1186/1475-2840-10-1, 3023678, 21214916.
44. Liu Y, Yang Y, Zhu J, Tan H, Liang Y, Li J. Prognostic significance of hemoglobin A1c level in patients hospitalized with coronary artery disease. A systematic review and meta-analysis. Cardiovascular Diabetology 2011, 10:1-9. 10.1186/1475-2840-10-1, 3023678, 21214916.
45. Verhagen SN, Wassink AMJ, van der Graaf Y, Gorter PM, Visseren FLJ. Insulin resistance increases the occurrence of new cardiovascular events in patients with manifest arterial disease without known diabetes. The SMART study. Cardiovascular Diabetology 2011, 10:100-108. 10.1186/1475-2840-10-100, 3268731, 22098712.
46. Yadegari H, Bozorgmanesh M, Hadaegh F, Azizi F. Non-linear contribution of glucose measures to cardiovascular diseases and mortality: Reclassifying the Framingham's risk categories: A decade follow-up from the Tehran lipid and glucose study. International Journal of Cardiology 2012, : - . Epub ahead of print.
47. Schinner S, Füth R, Kempf K, Martin S, Willenberg HS, Schott M, Dinh W, Scherbaum WA, Lankisch M. A progressive increase in cardiovascular risk assessed by coronary angiography in non-diabetic patients at sub-diabetic glucose levels. Significance 2011, 8:11.
48. Riddle MC. Counterpoint: Intensive Glucose Control and Mortality in ACCORD-Still Looking for Clues. Diabetes Care 2010, 33:2722. 10.2337/dc10-1658, 2992221, 21115778.
49. HOOGWERF BJ. Does intensive therapy of type 2 diabetes help or harm? Seeking accord on ACCORD. Cleveland Clinic Journal of Medicine 2008, 75:729-737. 10.3949/ccjm.75.10.729, 18939389.
50. Lim E, Hollingsworth K, Aribisala B, Chen M, Mathers J, Taylor R. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia 2011, 54:2506-2514. 10.1007/s00125-011-2204-7, 3168743, 21656330.
51. Fonseca V, Baron M, Shao Q, Dejager S. Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus. Hormone and metabolic research 2008, 40:427. 10.1055/s-2008-1058090, 18401832.
52. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001, 344:1343-1350. 10.1056/NEJM200105033441801, 11333990.
53. Harati H, Hadaegh F, Momenan AA, Ghanei L, Bozorgmanesh MR, Ghanbarian A, Mirmiran P, Azizi F. Reduction in incidence of type 2 diabetes by lifestyle intervention in a middle eastern community. Am J Prev Med 2010, 38:628-636. e621, 10.1016/j.amepre.2010.03.003, 20494239.
54. Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EAM, Howard BV, Kirkman MS, Kosiborod M, Reaven P. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials. Circulation 2009, 119:351-357. 10.1161/CIRCULATIONAHA.108.191305, 19095622.
55. Cohen A, Horton ES. Progress in the treatment of type 2 diabetes: new pharmacologic approaches to improve glycemic control. Current Medical Research and Opinion 2007, 23:905-917. 10.1185/030079907X182068, 17407648.
56. Nesto RW, Singh PP. Diabetes and residual risk of coronary heart disease. Nat Clin Pract End Met 2007, 3:71-71.